Pufferfish Skin Peptide Could Help Lower Blood Pressure
A peptide (FNLRMQ) derived from pufferfish skin collagen showed ACE-inhibiting activity and protected blood vessel cells from damage through Nrf2/HO-1 and PI3K/Akt/eNOS pathways.
Quick Facts
What This Study Found
The collagen-derived peptide FNLRMQ inhibits ACE activity and protects blood vessel endothelial cells from angiotensin II-induced injury through Nrf2/HO-1 and PI3K/Akt/eNOS signaling pathways.
Key Numbers
Peptide FNLRMQ; ACE inhibition confirmed; Nrf2/HO-1 and PI3K/Akt/eNOS pathways activated
How They Did This
Molecular docking to identify ACE-inhibitory peptides from pufferfish collagen hydrolysate, followed by in vitro testing on angiotensin II-induced HUVECs for cell viability, apoptosis, and signaling pathway analysis.
Why This Research Matters
High blood pressure affects over a billion people worldwide. Natural ACE-inhibiting peptides from marine sources could provide alternatives to synthetic ACE inhibitor drugs with potentially fewer side effects.
The Bigger Picture
Marine-derived bioactive peptides are an expanding area of pharmaceutical research. This study demonstrates that fish skin, often discarded as waste, can yield peptides with genuine therapeutic potential for cardiovascular health.
What This Study Doesn't Tell Us
In vitro study only using human cell lines. No animal or human trial data. Single peptide tested. Bioavailability and stability in the body not assessed.
Questions This Raises
- ?Would FNLRMQ lower blood pressure in animal models?
- ?How does this peptide's ACE inhibition compare to established drugs like lisinopril?
- ?Can the peptide survive digestion to reach the bloodstream?
Trust & Context
- Key Stat:
- Dual pathway protection FNLRMQ activated both Nrf2/HO-1 antioxidant and PI3K/Akt/eNOS vascular protective signaling
- Evidence Grade:
- In vitro study with human endothelial cells and clear mechanistic data. Preliminary evidence requiring animal model validation.
- Study Age:
- Published in 2021, part of growing interest in marine-derived bioactive peptides.
- Original Title:
- ACE Inhibitory Peptide from Skin Collagen Hydrolysate of Takifugu bimaculatus as Potential for Protecting HUVECs Injury.
- Published In:
- Marine drugs, 19(12) (2021)
- Authors:
- Cai, Shuilin, Pan, Nan(2), Xu, Min(2), Su, Yongchang, Qiao, Kun, Chen, Bei, Zheng, Bingde, Xiao, Meitian, Liu, Zhiyu
- Database ID:
- RPEP-05298
Evidence Hierarchy
Frequently Asked Questions
What is ACE and why does blocking it help blood pressure?
ACE (angiotensin-converting enzyme) produces angiotensin II, which constricts blood vessels and raises blood pressure. Blocking ACE reduces angiotensin II production, allowing blood vessels to relax and lowering blood pressure.
Could a fish skin peptide really become a blood pressure medication?
It's early-stage research, but marine-derived peptides that inhibit ACE are being actively studied. The challenge is ensuring these peptides survive digestion and reach the bloodstream in active form.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05298APA
Cai, Shuilin; Pan, Nan; Xu, Min; Su, Yongchang; Qiao, Kun; Chen, Bei; Zheng, Bingde; Xiao, Meitian; Liu, Zhiyu. (2021). ACE Inhibitory Peptide from Skin Collagen Hydrolysate of Takifugu bimaculatus as Potential for Protecting HUVECs Injury.. Marine drugs, 19(12). https://doi.org/10.3390/md19120655
MLA
Cai, Shuilin, et al. "ACE Inhibitory Peptide from Skin Collagen Hydrolysate of Takifugu bimaculatus as Potential for Protecting HUVECs Injury.." Marine drugs, 2021. https://doi.org/10.3390/md19120655
RethinkPeptides
RethinkPeptides Research Database. "ACE Inhibitory Peptide from Skin Collagen Hydrolysate of Tak..." RPEP-05298. Retrieved from https://rethinkpeptides.com/research/cai-2021-ace-inhibitory-peptide-from
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.